Article info
Commentary
Selecting the target population for new Alzheimer drugs: challenges and expectations
- Correspondence to Prof Edo Richard, Radboudumc, Nijmegen, Gelderland, Netherlands; Edo.Richard{at}radboudumc.nl
Citation
Selecting the target population for new Alzheimer drugs: challenges and expectations
Publication history
- Received July 28, 2021
- Accepted July 28, 2021
- First published August 16, 2021.
Online issue publication
January 18, 2022
Article Versions
- Previous version (18 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps
- How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
- Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: protocol for the ExPlas study
- Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances
- Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study
- The China Alzheimer Report 2022
- 28 A perfect storm: expanded disease definitions in alzheimer’s disease and the new era of disease-modifying drugs in mild cognitive impairment
- Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
- Cognitive symptoms of Alzheimer’s disease: clinical management and prevention
- FDA calls for investigation into industry influence during Alzheimer’s drug approval